A new form of S-ketamine in treatment of depression

Depression is the most common mental disorder in the modern world. Currently available depression treatments demonstrate therapeutic effects only after a couple of weeks of regular medication. The project aims at developing an innovative route of administration of a well-known anaesthetic which has immediate and long term antidepressant effects proven in several clinical trials over the last decade. This innovative technology, developed thanks to Celon Pharma’s experience, will not only patients to take medication on their own, but also control the administered dose.
The project envisions determining its pharmacokinetic profile and verifying its safety profile during toxicological tests to evaluate its efficacy in phase I and II clinical trials.

Total value of the DISK project: 23 356 704,41 PLN,while the total value of funding from the Smart Growth Operational Programme amounts to PLN 12 670 168,43